GlassScriptPhysician profile
Roy S Scheirer
NPI 1639131337
$12,358.60
in general payments reported to CMS, 2019-2025
42 companies · $1,956 in 2025
The $1,956 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,983 · 2022: $2,219 · 2023: $2,790 · 2024: $2,411 · 2025: $1,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,156.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,869.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,319.14 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,155.75 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $1,139.38 | 2021-2025 | Evenity, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $915.76 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $688.37 | 2021-2025 | Xifaxan, Ibschek |
| Pfizer INC. | $581.62 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $533.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $451.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $309.55 | 2021-2022 | |
| Abbvie INC. | $295.75 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $254.77 | 2021-2022 | |
| Esperion Therapeutics, INC. | $251.87 | 2021-2025 | Nexletol |
| Intuity Medical INC | $243.40 | 2022 | |
| Medtronic, INC. | $168.82 | 2024 | Reveal Linq |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Scheirer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.